In Vitro Metabolism of Donepezil in Liver Microsomes Using Non-Targeted Metabolomics.

ABSTRACT: Donepezil is a reversible acetylcholinesterase inhibitor that is currently the most commonly prescribed drug for the treatment of Alzheimer's disease. In general, donepezil is known as a safe and well-tolerated drug, and it was not associated with liver abnormalities in several clinical trials. However, rare cases of drug-related liver toxicity have been reported since it has become commercially available. Few studies have investigated the metabolic profile of donepezil, and the mechanism of liver damage caused by donepezil has not been elucidated. In this study, the in vitro metabolism of donepezil was investigated using liquid chromatography-tandem mass spectrometry based on a non-targeted metabolomics approach. To identify metabolites, the data were subjected to multivariate data analys

SUBMITTER: Kim SE 

PROVIDER: S-EPMC8309179 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature